Amgen Hits Double-Digit Growth in 13 Products, Biosimilars Sales Up 37%
Amgen exited 2025 with 13 products posting double-digit growth, 14 exceeding $1 billion in annual sales and 18 delivering record performance, driving double-digit revenue and EPS gains. Its key franchises—Repatha, EVENITY and TEZSPIRE—each grew over 30%, while rare disease sales reached $5 billion (+14%) and biosimilars hit $3 billion (+37%).
1. Portfolio Momentum
Amgen exited 2025 with 13 products delivering double-digit growth, 14 exceeding $1 billion in annual sales and 18 logging record performance, supporting double-digit increases in both revenue and earnings per share.
2. Key Growth Franchises
Repatha, EVENITY and TEZSPIRE each grew more than 30% year-over-year, establishing themselves as multi-billion-dollar global franchises with projected growth potential throughout the decade.
3. Rare Disease Segment
The rare disease portfolio generated $5 billion in sales, up 14%, driven by geographic expansion, new patient adoption and additional indications, with UPLIZNA sales jumping 73% following its launch.
4. Biosimilars Performance
Biosimilars sales rose 37% to $3 billion, led by PAVBLU’s estimated $700 million in annual revenue, while candidates targeting OPDIVO, KEYTRUDA and Ocrevus advance through phase III development.